Factors, including transforming growth factor β, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells

Cancer Immunology Immunotherapy

Volumn 36, Issue 6, 1993, Pages 409-416

  Ruffini, Pier Adelchi ^a   Rivoltini, Licia ^a   Silvani, Antonio ^b   Boiardi, Amerigo ^b   Parmiani, Giorgio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

A LAK cells; Glioblastoma; In vivo immunosuppression; TGF

Indexed keywords

RECOMBINANT INTERLEUKIN 2; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; GLIOBLASTOMA; HUMAN; HUMAN CELL; LYMPHOKINE ACTIVATED KILLER CELL; PRIORITY JOURNAL;

CELL ADHESION; CYTOTOXICITY, IMMUNOLOGIC; GLIOMA; GROWTH INHIBITORS; HUMAN; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTE ACTIVATION; TRANSFORMING GROWTH FACTOR BETA;

EID: 0027230932     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/BF01742258     Document Type: Article

References (37)

1. Immunosuppression and transforming growth factor-β in glioblastoma. Preferential production of transforming growth factor-β2
2. Depressed cell-mediated immunity in patients with primary intracranial tumors
3. Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-β gene family
4. Suppression of high affinity IL-2 receptors on mitogen activated lymphocytes by gliomaderived suppressor factor
5. Transforming growth factor-β1 (TGF-β1) and recombinant human tumor necrosis factor-α reciprocally regulate the generation of lymphokineactivated killer cell activity. Comparison between natural porcine platelet-derived TGF-β1 and TGF-β2, and recombinant human TGF-β1
6. Glioblastoma cells release interleukin-1 and factors inhibiting interleukin-2 mediated effects
7. Transforming growth factor-β inhibits the generation of cytotoxic T cells in virus-infected mice
8. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor-β1
9. Blocking factors (soluble receptors) for human TNF and LT in the serum, cerebrospinal fluid (CSF) and tumor cyst fluid (TCF) of human glioma patients
10. Effect of LAK cells against three-dimensional tumor tissue. In vitro study using multi-cellular human glioma spheroids as targets
11. Migration of recombinant IL-2-activated T and natural killer cells in the intercellular space of human H-2 glioma spheroids in vitro. A study on adhesion molecules involved
12. Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma
13. Production of transforming growth factor-β by human T lymphocytes and its potential role in the regulation of T cell growth
14. The glioblastoma-derived T-cell suppressor factor/transforming growth factor-β2 inhibits the generation of lymphokine-activated killer (LAK) cells
15. Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor-β2
16. Influence of PGE2 and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2 activated lymphocytes
17. Immunobiology of primary intracranial tumors. Part I. Studies of the cellular and humoral general immune competence of brain tumor patients
18. A new approach to generating antitumor effectors for adoptive immunotherapy using adherent lymphokine-activated killer cells
19. Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of preclinical and clinical investigations
20. Transforming growth factor-β inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells
21. Preliminary trial of specific targeting therapy against malignant glioma
22. Lymphocyte infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate and relevance to prognosis in 228 operated cases
23. Inhibition of cytotoxic T cell development by transforming growth factor-β and reversal by recombinant tumor necrosis factor α
24. The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype
25. Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumors, with a characterization of the tumor phenotype
26. Effects of transforming growth factor-β on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness
27. Modulation of T-cell function by gliomas
28. Assessment of cytokines by immunofluorescence and the paraformaldehyde-saponin procedure
29. In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes
30. Immunotherapy and monoclonal antibody therapies
31. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic
32. Partial purification and biochemical characterization of a T cell suppressor factor produced by human glioblastoma cells
33. The glioblastoma-derived T cell suppressor factor/transforming growth factor-β2 inhibits T cell growth without affecting the interaction of interleukin-2 with its receptor
34. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-β
35. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance
36. Treatment of gliomas in adults
37. In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors